at call am good Medical. on everyone Journey on to today. making that progress Thank you, report afternoon we to are Jaclyn, I and the ongoing pleased the
guidance annual results to that $XX.X we our second million. XXXX on product second to million believe track remain Our of were meet We $XX demonstrates range our million $XX performance solid revenue with net revenue. in quarter that quarter
prescription our With base X for of our quarter believe greater dermatology that network, rosacea. second prescriptions of we physicians also November XX% in our direct we on We DFD-XX, already as our for candidate commercial organization date business unity. cash, calling we the of generate our for product core than portfolio await brands leverage strength that the generating believe well results written highlight to DFD-XX are operating PDUFA dermatology
by QBREXZA during of million Accutane Looking to TRxs grew QX and approximately at year. period. product compared brands, And the our revenue the together prescriptions XXXX. same Acute contributed for this prescriptions for XX,XXX by QX top when net $XX.X QBREXZA X,XXX grew in
team we marketing both was expanded brands are with This both and and our to share efforts achieved in Accutane the by trade network. expansion in particular, respective pharmacy adoption reach our and access of our prescriber and pleased our of QBREXZA that group. In sales their through report categories. of combination market a our gained Additionally, has
more than Accutane this AMZEEQ, for of revenue. these X Looking XX% core quarterly of brands, our at and products performance ZILXI commercial our during quarter, QBREXZA, accounted the
Dr. such portfolio NDA products these milestone payment DFD-XX prelaunch our onetime of for we generated acceptance. revenues expenses, have Importantly, a million of recent surpassed Simply excluding $X.X that operating put, fee for NDA Reddy's product from we positive million with infrastructure. the expenses to the of and as contribution the generated commercial $X optimized filing from support our our made core the
that results. the fourth we adjusted consecutive EBITDA results, this non-GAAP delivered our achieved solid adjusted quarter. that to $XXX,XXX positive report the top line in we of am EBITDA very to second quarter I addition In pleased is
while maintaining key to our strategic sales has a marketing revenue our and from product of factor been rationalization Our the our headcount profitability base initiative expenses including SG&A in significantly XXXX. reduce improving
beginning to total our and enabling our expenses the approximately by retain when costs this $XX us of million. reduced from Since contain sales. we've began, more initiative XXXX, cash generated
Importantly, leverage anticipated DFD-XX. of puts to strong the financial in position a launch discipline our us
goal the coming in become to quarters XXXX. sustainably positive cash flow and the With positive EBITDA
Given that of and from and prescriptions treat anticipated United in the rosacea year main to more preparing With the States people than objectives suffering XX.X profitability; focused DFD-XX. filled X million we our improve to in remain our year: achieving this for financial alone our the First, for second, guidance X million approximately approval each continuing and and launch condition.
believe opportunity company. for that a the DFD-XX growth significant We provides
placebo clinical the were sales you had TRx current Phase oral inflammatory DFD-XX co-primary in both over our of and recall, and reduction with million endpoints, weight lesions the statistical prescribers associated standard both will $XXX which On III both DFD-XX and against rosacea As and success clinically market-leading many and to trial as care superiority Clinical annual compelling. results studies Oracea, for initially in demonstrated we with for rosacea. the DFD-XX position of of significant positive very carry Oracea treatment trials XXXX. plans health IGA
that III is for XX Erythema profile, patient accelerate result topical with redness our rosacea skin both meaningful ability We product Additionally, approved, a associated The States can and Phase help and $X.X both annually. the the in for prescriber our rosacea. the from treatments United demonstrated adoption. trials, DFD-XX's if this clinical believe approximately products oral billion differentiate or market in can and reduce Phase III to is significantly program
label, the be DFD-XX's With market. we erythema broader share will and to indication believe DFD-XX positioned take anticipated the of treatment of rosacea
the for this similar safety placebo. confidence in us and regulatory gives high also results as demonstrated This to later the and results DFD-XX, clinical package potential as DFD-XX with well Our were that Phase favorable market approval profile tolerability III for a year.
this commercial both potential rosacea participants. sets may which in assess plans leading feedback recall, As and The surveyed was prescribers positive for very we of you to of we of the research earlier market treatments conducted insurance year, adoption DFD-XX.
of as III results significant adoption the in our compelling as expressed XX%. Given patients care internal was positive a rate which results. erythema a rosacea Health well DFD-XX This for expectations. prescribers prescribe willingness Oracea, to own statistical exceeded with Phase strong placebo the against result, an their
For million which covered our PBMs, GPOs showed most, other care represented interview are us likely all, that XXX payers, and the for coverage contract organizations lives, survey managed to of not over provide if collectively to with DFD-XX.
specialty reimbursement that to has with focus DFD-XX We that of demonstrates favorable, negotiations market property. component believe is be on inclusion intellectual research and assuming approved. of products will building strong with a this the A acceptance among for high been creation will prescribers DFD-XX and strategy payers formulary key value our dermatology have portfolio
'XX. with of in have and current exclusivity settlements for exclusivity result litigation to current patent ZILXI with exclusivity XXXX, AMZEEQ patent runway a and As of our patent with to we XXXX a to XXXX patent current strong patent XXXX. QBREXZA exclusivity
our XXXX. also portfolio will to providing DFD-XX add exclusivity until Importantly,
without track result, market strong exclusivity business intrusion foreseeable With a in record having development we the anticipate we As future. have community on presence dermatology focus a generic our for for products. the and prescription segment, the dermatology
we and result, property States. for primary United evaluating the a focus a A and to is to capable our shareholder continue company enhance to related value. intellectual opportunities As for interested the technologies effort outside out-license to companies have of robust
last $XX for in resulted to rights the million the countries. nondilutive company to Maruho capital year. out-licensing the Similar transaction of Asian QBREXZA certain to in This transaction
will and well globally and the ZILXI QBREXZA, to as to in our We technologies IP DFD-XX monetize for future. continue AMZEEQ explore as
will strong patients. and And will for our we to market in-license results continue focused survey customers in evaluate landscape product their where that we infrastructure. unmet can leverage opportunities trial to our dermatology clinical can commercial Additionally, demonstrated the dermatology late-stage candidates to also and we have we for product indications revenue-generating acquire that needs satisfy physician or continue
top that with for or the quarter. allow more will turn I and with Joe review adding bring financial opportunities product to call on Benesch, results second CFO, investment, to in executing both believe additional one bottom We And lines. our over now our these minimal to of that, to the revenue us would our
